Skip to main content
Erschienen in: Supportive Care in Cancer 4/2015

01.04.2015 | Original Article

Assessment of radiation-induced xerostomia: validation of the Italian version of the xerostomia questionnaire in head and neck cancer patients

verfasst von: Federica Pellegrino, Elena Groff, Luca Bastiani, Bruno Fattori, Guido Sotti

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Xerostomia is the most common acute and late side effect of radiation treatment for head and neck cancer. Affecting taste perception, chewing, swallowing and speech, xerostomia is also the major cause of decreased quality of life. The aims of this study were to validate the Italian translation of the self-reported eight-item xerostomia questionnaire (XQ) and determine its psychometric properties in patients treated with radiotherapy for head and neck cancer.

Methods

An observational cross-sectional study was conducted in the Radiotherapy Unit of the Veneto Institute of Oncology – IOV in Padua. The XQ was translated according to international guidelines and filled out by 102 patients. Construct validity was assessed using principal component analysis, internal consistency using Cronbach’s α coefficient and test-retest reliability at 1-month interval using the intraclass correlation coefficient (ICC). Criterion-related validity was evaluated to compare the Italian version of XQ with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire (QLQ-C30) and its Head and Neck Cancer Module (QLQ-H&N35).

Results

Cronbach’s α for the Italian version of XQ was strong at α = 0.93, test-retest reliability was also strong (0.79) and factor analysis confirmed that the questionnaire was one-dimensional. Criterion-related validity was excellent with high association with the EORTC QLQ-H&N35 xerostomia and sticky saliva scales.

Conclusions

The Italian version of XQ has excellent psychometric properties and can be used to evaluate the impact of emerging radiation delivery techniques aiming at preventing xerostomia.
Literatur
2.
Zurück zum Zitat Langendijk JA, Doornaert P, Verdonack-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770–3776CrossRefPubMed Langendijk JA, Doornaert P, Verdonack-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770–3776CrossRefPubMed
3.
Zurück zum Zitat Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, Scarantino C, Brizel D (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13:226–234CrossRefPubMed Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, Scarantino C, Brizel D (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13:226–234CrossRefPubMed
4.
Zurück zum Zitat Jo D, Moiseenko V, Marks L, Chao C, Nam J, Eisbruch A (2010) Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol 76(1):S58–S63 Jo D, Moiseenko V, Marks L, Chao C, Nam J, Eisbruch A (2010) Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol 76(1):S58–S63
5.
Zurück zum Zitat Vissink A, Jansma J, Spijkervet FKL, Buriage FR, Coppes RP (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212CrossRefPubMed Vissink A, Jansma J, Spijkervet FKL, Buriage FR, Coppes RP (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212CrossRefPubMed
7.
Zurück zum Zitat Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A (2006) Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol 60(2):445–453CrossRef Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A (2006) Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol 60(2):445–453CrossRef
8.
Zurück zum Zitat Eisbruch A, Kim HM, Terrel JE, Marsh LH, Dawson LA, Ship JA (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol 50(3):695–704CrossRef Eisbruch A, Kim HM, Terrel JE, Marsh LH, Dawson LA, Ship JA (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol 50(3):695–704CrossRef
9.
Zurück zum Zitat Lin SC, Jen YM, Chang YC, Lin CC (2008) Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of the xerostomia questionnaire. J Pain Symptom Manag 36(2):141–148CrossRef Lin SC, Jen YM, Chang YC, Lin CC (2008) Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of the xerostomia questionnaire. J Pain Symptom Manag 36(2):141–148CrossRef
10.
Zurück zum Zitat Marucci L, Marzi S, Sperduti I, Giovinazzo G, Pinnarò P, Benassi M, Strigari L (2012) Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer. Head Neck 34(3):328–335CrossRefPubMed Marucci L, Marzi S, Sperduti I, Giovinazzo G, Pinnarò P, Benassi M, Strigari L (2012) Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer. Head Neck 34(3):328–335CrossRefPubMed
11.
Zurück zum Zitat Jabbari S, Kim HM, Feng M, Lin A, Tsien C, Elshaikh M, Terrel E, Murdoch-Kinch C, Eisbruch A (2005) Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol 63(3):725–731CrossRef Jabbari S, Kim HM, Feng M, Lin A, Tsien C, Elshaikh M, Terrel E, Murdoch-Kinch C, Eisbruch A (2005) Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol 63(3):725–731CrossRef
12.
Zurück zum Zitat Pacholke HD, Amdur RJ, Morris CG, Li JG, Dempsey JF, Hinerman RW, Mendenhall WM (2005) Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol 28:351–358CrossRefPubMed Pacholke HD, Amdur RJ, Morris CG, Li JG, Dempsey JF, Hinerman RW, Mendenhall WM (2005) Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol 28:351–358CrossRefPubMed
13.
Zurück zum Zitat Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46:1417–1432CrossRefPubMed Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46:1417–1432CrossRefPubMed
14.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed
15.
Zurück zum Zitat Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, Ahlner-Elmqvist M, Maher EJ, Meyza JW, Brédart A, Söderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P, Bottomly A, Kaasa S (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36:1796–1807CrossRefPubMed Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, Ahlner-Elmqvist M, Maher EJ, Meyza JW, Brédart A, Söderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P, Bottomly A, Kaasa S (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36:1796–1807CrossRefPubMed
16.
Zurück zum Zitat Nunnely JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York Nunnely JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
17.
Zurück zum Zitat Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334CrossRef Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334CrossRef
18.
Zurück zum Zitat Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18:1039–1060CrossRefPubMed Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18:1039–1060CrossRefPubMed
19.
Zurück zum Zitat Kaiser H (1970) A second generation little jiffy. Psychometrika 35:401–415CrossRef Kaiser H (1970) A second generation little jiffy. Psychometrika 35:401–415CrossRef
20.
Zurück zum Zitat Cattell R (1966) The screen test for the number of factors. Multivar Behav Res 1:245–276CrossRef Cattell R (1966) The screen test for the number of factors. Multivar Behav Res 1:245–276CrossRef
21.
Zurück zum Zitat Lin A, Kim HM, Terrel JE, Dawson LA, Ship JA, Eisbruch A (2003) Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol 57:61–70CrossRef Lin A, Kim HM, Terrel JE, Dawson LA, Ship JA, Eisbruch A (2003) Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol 57:61–70CrossRef
22.
Zurück zum Zitat Beetz I, Burlage FR, Bijl HP, Hoegen-Chouvalova O, Christianen M, Vissink A, van der Laan B, de Bock G, Langendijk JA (2010) The Groningen radiotherapy-induced xerostomia questionnaire: development and validation of a new questionnaire. Radiother Oncol 97:127–131CrossRefPubMed Beetz I, Burlage FR, Bijl HP, Hoegen-Chouvalova O, Christianen M, Vissink A, van der Laan B, de Bock G, Langendijk JA (2010) The Groningen radiotherapy-induced xerostomia questionnaire: development and validation of a new questionnaire. Radiother Oncol 97:127–131CrossRefPubMed
23.
Zurück zum Zitat Nutting CM, Morden JP, Harrington KJ et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136CrossRefPubMedCentralPubMed Nutting CM, Morden JP, Harrington KJ et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Kakoei S, Haghdoost AA, Rad M, Mohammadalizadch S, Pourdamghan N, Nakhaei M, Bahador M (2012) Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Arch Iran Med 15(4):214–218PubMed Kakoei S, Haghdoost AA, Rad M, Mohammadalizadch S, Pourdamghan N, Nakhaei M, Bahador M (2012) Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Arch Iran Med 15(4):214–218PubMed
25.
Zurück zum Zitat Beetz I, Schilstra C, Burlage FR, Koken PW, Doornaert P, Bijl HP, Chouvalova O, Leemans CR, de Bock GH, Christianen ME, van der Laan BF, Vissink A, Steenbakkers RJ, Lamgedijk JA (2012) Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. Radiother Oncol 105:86–93CrossRefPubMed Beetz I, Schilstra C, Burlage FR, Koken PW, Doornaert P, Bijl HP, Chouvalova O, Leemans CR, de Bock GH, Christianen ME, van der Laan BF, Vissink A, Steenbakkers RJ, Lamgedijk JA (2012) Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. Radiother Oncol 105:86–93CrossRefPubMed
26.
Zurück zum Zitat Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch AC, Eisbruch A (2012) Reducing xerostomia after chemo-IMRT for head and neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 83(3):1007–1014CrossRefPubMedCentralPubMed Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch AC, Eisbruch A (2012) Reducing xerostomia after chemo-IMRT for head and neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 83(3):1007–1014CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Citak E, Tulek Z (2013) Longitudinal quality of life in Turkish patients with head and neck cancer undergoing radiotherapy. Support Care Cancer 21:2171–2183CrossRefPubMed Citak E, Tulek Z (2013) Longitudinal quality of life in Turkish patients with head and neck cancer undergoing radiotherapy. Support Care Cancer 21:2171–2183CrossRefPubMed
Metadaten
Titel
Assessment of radiation-induced xerostomia: validation of the Italian version of the xerostomia questionnaire in head and neck cancer patients
verfasst von
Federica Pellegrino
Elena Groff
Luca Bastiani
Bruno Fattori
Guido Sotti
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2438-2

Weitere Artikel der Ausgabe 4/2015

Supportive Care in Cancer 4/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.